
usd feb pm et
summari make diagnost product medic imag system surgic product
emphasi women health also make medic aesthet system
nm price-to-earnings oper ep
risk assess reflect particip
industri character rapid technolog chang new
industri standard new market entrant addit
compet number compani
significantli greater resourc product depth
includ ge siemen phillip fuji kodak toshiba
howev maintain healthi reput solid
market share breast imag gynecolog
apr ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
expect sale decreas fy
sep billion primarili due
divestitur holx cynosur busi
follow growth fy
fy respect organ basi
anticip sale growth like driven
holx molecular diagnost breast
health busi togeth compris
holx revenu
build increasingli
comprehens product portfolio breast
health effort recent
tuck-in acquisit near term
expect continu priorit tuck-in
acquisit share repurchas especi
sinc larg transact work
well compani exampl
acquir cynosur march
billion divest decemb
paltri million
expect adjust gross margin improv
basi point bp fy
margin pressur prior year headwind
yoy due higher manufactur
trade tariff product mix
think share trade
valu see sustain recur revenu
molecular diagnost busi
compani domin market share
certain assay categori
success driven increas util
diagnost machin grow assay
menu evidenc grow averag
revenu per panther system -- fy
vs fy think
effort expand breast health product
portfolio help expand firm alreadi
domin share mammographi
market long-term see opportun
enhanc offer
artifici intellig tool compani
current develop aim launch
risk recommend target price
includ weak perform intern
market competit pressur failur
innov unfavor chang
reimburs clinic guidelin
target price
ep estim
compar forward price-to-earnings rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop manufactur supplier premium diagnost
product medic imag system surgic product light-bas aesthet medic treatment
system emphasi women health oper five segment diagnost
total revenu year end septemb breast health medic aesthet
gyn surgic skelet health sell servic product
combin direct sale servic personnel network independ distributor sale
offer wide rang diagnost product use primarili aid diagnosi human
diseas primari diagnost product includ holx aptima famili diagnost assay run
holx advanc instrument system panther tigri thinprep system rapid fetal
fibronectin test aptima famili molecular diagnost assay use detect among thing
infecti microorgan caus common sexual transmit diseas std
chlamydia gonorrhea certain high-risk strain human papillomaviru hpv trichomona
vaginali parasit caus trichomoniasi
breast health product includ broad portfolio breast imag relat product accessori
includ digit mammographi system computer-aid detect cad mammographi
minim invas breast biopsi devic breast biopsi site marker breast biopsi guidanc system
holx advanc breast imag platform selenia dimens util
technolog call tomosynthesi produc imag show multipl contigu slice imag
breast refer geniu mammographi exam
medic aesthet segment offer portfolio aesthet treatment system sculpsur
enabl plastic surgeon dermatologist medic practition perform non-invas
minim invas procedur remov hair treat vascular benign pigment lesion remov
multi-color tattoo revit skin reduc fat laser lipolysi reduc cellulit clear nail
infect toe fungu ablat sweat gland improv gynecolog health novemb
execut definit agreement sell medic aesthet busi disposit expect
close year-end
gyn surgic segment make product aim toward gynecolog health novasur
endometri ablat system myosur hysteroscop tissu remov system skelet health
segment offer product bone densitomet imag system use assist
perform minim invas surgic procedur patient extrem
competit landscap holx wide array product face competit varieti
competitor includ competitor even broader product portfolio great brand recognit
current environ manag care economically-motiv buyer consolid among
healthcar provid increas competit declin reimburs rate
increasingli requir compet basi price valu reliabl effici
impact major develop novemb announc divest cynosur
medic aesthet busi million signific difficulti cynosur busi
sinc acquir march billion lead signific impair charg
major develop fiscal although compani made sever tuck-in
januari divest blood screen busi grifol sale price
billion august acquir gen-prob lead maker molecular diagnost product
billion june acquir tct intern co ltd privat held distributor
medic product china acquisit tct provid establish nationwid sale
organ custom support infrastructur china
financi trend revenu grew billion fy sep billion prior year
five-year compound annual growth rate compound-annual-growth-rate adjust earn per share expand
fy fy five-year compound-annual-growth-rate adjust ep fy
free cash flow defin cash flow oper less capit expenditur million
million fy given net debt total capit ratio septemb
expect make larg acquisit near futur howev think opportunist
tuck-in acquisit like holx manag point acquisit core part
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
maintain target ep
estim multipl near middl averag ratio
keep fy sep ep estim fy ep
dec-q ep vs higher estim sale rose
slightli ahead expect driven growth breast health
increas global molecular diagnost posit view intern
revenu growth constant currenc domest sale rose
less stellar gross margin narrow basi point hurt less favor
geograph product sale mix posit view closur focal
therapeut acquisit strengthen posit breast-conserv
surgeri see progress breast health global molecular diagnost
support top-lin growth excess deploy support
tuck-in acquisit share repurchas kevin huang cfa angelo zino cfa
et cfra retain hold opinion share inc
maintain target ep
estim multipl near middl averag
ratio sep-q ep vs lower estim
lower fy sep ep initi fy
ep sep-q sale increas constant currenc
million difficult comparison divestitur
blood screen busi non-recurring royalti revenu molecular
aesthet declin cc gyn surgic grew cc
acquir cynosur busi continu headwind due unfavor
fda letter also announc two tuck-in acquisit faxitron focal
therapeut intend continu priorit tuck-in acquisit
capit alloc /kevin huang cfa
analyst research note compani news
et cfra keep hold opinion share inc
lift target price base forward price-to-earnings
multipl ep estim multipl
toward middl holx five-year forward price-to-earnings rang
lift fy sep ep estim fy
ep dec-q ep vs fell short
expect sale grew constant currenc cc
million slightli expect recent divestitur result
lower sale exclud recent divestitur acquisit grew
cc basi dec-q cc basi diagnost busi grew
breast health gyn surgic skelet health decemb
complet divestitur cynosur busi cyno
weigh result fy expect capit deploy
primarili focus tuck-in acquisit share buyback /kevin huang
et cfra reiter hold opinion share inc
lift target base forward price-to-earnings
multipl ep estim multipl
toward middl five-year forward price-to-earnings rang
keep fy sep ep estim initi fy ep
sep-q ep vs equal expect sale
grew constant currenc cc million led
cc growth medic aesthet easi comp follow gyn
surgic diagnost breast health initi fy
cc revenu growth guidanc seem achiev us
gross margin declin basi point bp yoy
expect primarili due higher manufactur cost foreign exchang
china trade tariff product mix anticip headwind
pressur margin abat fy lead bp full-year
et cfra maintain hold opinion share inc
lift target base forward price-to-earnings
multipl ep estim rais
sep ep estim ep
jun-q ep vs estim sale rose
constant currenc cc million ahead
expect driven global cc growth global molecular
diagnost busi recent tuck-in acquisit faxitron focal
acceler growth gyn surgic busi sale
outsid grew cc slower recent quarter
macroeconom polit challeng compani latin american busi
primarili breast health focus unlik previou quarter --
adjust oper margin declin basi point bp due sever
one-tim item -- adjust oper margin improv bp yoy
jun-q /kevin huang cfa
et cfra keep hold opinion share inc
lift target base multipl
ep estim multipl equal
averag forward price-to-earnings ratio adjust fy sep ep estim
mar-q ep vs equal estim sale rose
constant currenc cc million slightli
ahead expect led global cc growth breast health
busi follow cc growth diagnost exclud blood
busi adjust oper margin deterior basi point
mar-q primarili declin gross margin
neg affect sever one-tim item inventori reserv scrap
charg unfavor foreign exchang movement also wrote-down
million asset medic aesthet busi mar-q respons
neg trend compani previous note /kevin huang cfa
et cfra keep hold opinion share inc
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
